Bioventus Inc. (BVS)Healthcare | Medical Devices | Durham, United States | NasdaqGS
12.07 USD
+0.19
(1.599%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 12.07 |
Hot Take ↕ | July 11, 2026, 5:04 a.m. EDT
The immediate outlook is aggressively bullish, driven by a powerful technical rebound and a massive divergence between call and put positioning. After a brutal multi-year decline where the stock lost nearly 60% of its value, the company has staged a remarkable recovery, trading near its 52-week highs. This resurgence is attracting heavy speculative capital, evidenced by the overwhelming call open interest in the coming months and the complete absence of protective put buying. While the statistical forecast model offers a weak, noisy signal to the downside, it is clearly irrelevant in the face of such strong momentum and fundamental re-rating. The market appears to be pricing in a successful turnaround story, moving the stock from a deep value trap into a high-conviction growth play. However, investors must remain cautious regarding the long-term horizon; the company still lacks a dividend safety net, and while the recent price action is stellar, the path to sustaining this valuation requires consistent execution in a competitive medical device landscape. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.081352 |
| AutoETS | 0.081920 |
| AutoARIMA | 0.081921 |
| MSTL | 0.082820 |
| MSTL_48 | 0.083712 |
| MSTL_105 | 0.145340 |
| MSTL_48_105 | 0.152378 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 7.58 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.673 |
| Excess Kurtosis | -0.45 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 123.117 |
| Revenue per Share | 8.609 |
| Market Cap | 817,718,912 |
| Trailing P/E | 29.44 |
| Forward P/E | 13.29 |
| Beta | 0.65 |
| Profit Margins | 4.94% |
| Website | https://www.bioventus.com |
As of July 11, 2026, 5:04 a.m. EDT: Speculators are heavily positioned for upside in the near term, with July and August call open interest significantly outweighing put open interest. Traders are betting on a continuation of the recent rally, targeting strikes above the current price. Conversely, there is virtually no speculative put volume beyond the immediate expiration, indicating a lack of hedging against a near-term crash despite the stock's volatile history.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.74449337 |
| Address1 | 4,721 Emperor Boulevard |
| Address2 | Suite 100 |
| All Time High | 19.941 |
| All Time Low | 0.8 |
| Ask | 15.27 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 895,750 |
| Average Daily Volume3 Month | 651,696 |
| Average Volume | 651,696 |
| Average Volume10Days | 895,750 |
| Beta | 0.653 |
| Bid | 8.76 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 2.793 |
| City | Durham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 12.07 |
| Current Ratio | 1.687 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 12.26 |
| Day Low | 11.79 |
| Debt To Equity | 123.117 |
| Display Name | Bioventus |
| Earnings Call Timestamp End | 1,778,070,600 |
| Earnings Call Timestamp Start | 1,778,070,600 |
| Earnings Timestamp | 1,778,070,600 |
| Earnings Timestamp End | 1,785,846,600 |
| Earnings Timestamp Start | 1,785,846,600 |
| Ebitda | 80,897,000 |
| Ebitda Margins | 0.14037 |
| Enterprise To Ebitda | 13.791 |
| Enterprise To Revenue | 1.936 |
| Enterprise Value | 1,115,656,960 |
| Eps Current Year | 0.78 |
| Eps Forward | 0.908 |
| Eps Trailing Twelve Months | 0.41 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 9.7641 |
| Fifty Day Average Change | 2.3058996 |
| Fifty Day Average Change Percent | 0.236161 |
| Fifty Two Week Change Percent | 74.44933 |
| Fifty Two Week High | 12.3 |
| Fifty Two Week High Change | -0.2300005 |
| Fifty Two Week High Change Percent | -0.018699227 |
| Fifty Two Week Low | 5.81 |
| Fifty Two Week Low Change | 6.2599998 |
| Fifty Two Week Low Change Percent | 1.0774527 |
| Fifty Two Week Range | 5.81 - 12.3 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,613,053,800,000 |
| Float Shares | 33,305,618 |
| Forward Eps | 0.908 |
| Forward P E | 13.292952 |
| Free Cashflow | 63,310,876 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 940 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.68692 |
| Gross Profits | 395,870,016 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.117469996 |
| Held Percent Institutions | 0.78239 |
| Implied Shares Outstanding | 67,748,048 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ipo Expected Date | 2,021-02-11 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina. |
| Long Name | Bioventus Inc. |
| Market | us_market |
| Market Cap | 817,718,912 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_154172707 |
| Most Recent Quarter | 1,774,656,000 |
| Net Income To Common | 28,482,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 804,846,810 |
| Number Of Analyst Opinions | 5 |
| Open | 12.06 |
| Operating Cashflow | 102,938,000 |
| Operating Margins | 0.0673 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.51 |
| Phone | 919 474 6700 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 12.07 |
| Post Market Time | 1,783,981,119 |
| Previous Close | 11.88 |
| Price Eps Current Year | 15.4743595 |
| Price Hint | 2 |
| Price To Book | 4.321518 |
| Price To Sales Trailing12 Months | 1.4189118 |
| Profit Margins | 0.04942 |
| Quick Ratio | 1.056 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.4 |
| Region | US |
| Regular Market Change | 0.19 |
| Regular Market Change Percent | 1.59932 |
| Regular Market Day High | 12.26 |
| Regular Market Day Low | 11.79 |
| Regular Market Day Range | 11.79 - 12.26 |
| Regular Market Open | 12.06 |
| Regular Market Previous Close | 11.88 |
| Regular Market Price | 12.07 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 654,378 |
| Return On Assets | 0.05613 |
| Return On Equity | 0.16459 |
| Revenue Growth | 0.066 |
| Revenue Per Share | 8.609 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 67,748,048 |
| Shares Percent Shares Out | 0.0322 |
| Shares Short | 2,184,427 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,842,216 |
| Short Name | Bioventus Inc. |
| Short Percent Of Float | 0.0471 |
| Short Ratio | 3.11 |
| Source Interval | 15 |
| State | NC |
| Symbol | BVS |
| Target High Price | 16.0 |
| Target Low Price | 14.0 |
| Target Mean Price | 14.8 |
| Target Median Price | 15.0 |
| Total Cash | 35,846,000 |
| Total Cash Per Share | 0.529 |
| Total Debt | 288,420,000 |
| Total Revenue | 576,300,032 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.41 |
| Trailing P E | 29.439024 |
| Trailing Peg Ratio | 1.5134 |
| Triggerable | 1 |
| Two Hundred Day Average | 8.419575 |
| Two Hundred Day Average Change | 3.650425 |
| Two Hundred Day Average Change Percent | 0.43356407 |
| Type Disp | Equity |
| Volume | 654,378 |
| Website | https://www.bioventus.com |
| Zip | 27,703 |